Skip to main content
SpringerLink
Log in

Individualizing Antihypertensive Combination Therapies: Clinical and Hemodynamic Considerations

  • Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

While there are strong trial data to guide the selection of initial hypertension treatment choice and limited data to support second agent choice, beyond the first two agents, subsequent steps are empiric. As medications are added, the resulting polypharmacy may be complex, inefficient and poorly tolerated, resulting in low treatment adherence rates. The selection of antihypertensive drug therapy based on hemodynamic mechanisms is not new but became practical with the availability of noninvasive hemodynamic parameters using impedance cardiography. Individualized therapy based on hormonal or hemodynamic measurements can effectively control hypertension as shown in several small clinical trials. Hemodynamic measurements are obtained quickly, painlessly and can be used in a serial fashion to guide treatment adjustments. Current limitations relate to availability of the measurement device and personnel trained in its use, reimbursement for the measurements, expertise in interpretation of the measurements and systems to adjust medication and repeat measurements in a serial fashion until targets are attained. The potential utility of this approach increases with greater complexity of the medication regimen. Further studies are indicated and may advance options for individualized treatment of hypertensive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J, et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.

    Article  CAS  PubMed  Google Scholar 

  2. National Institute for Health and Clinical Excellence (NICE): Hypertension: The clinical management of primary hypertension in adults. 2011.

  3. Frieden T. Protocol-Based Treatment of Hypertension: A Critical Step on the Pathway to Progress. JAMA. 2014;311:21–2. Viewpoint arguing for standardized treatment approaches to hypertension using protocols, algorithms and care pathways.

    Article  CAS  PubMed  Google Scholar 

  4. Taler SJ, Textor SC, Augustine JE. Resistant Hypertension: Comparing hemodynamic management to specialist care. Hypertension. 2002;39:982–8.

    Article  CAS  PubMed  Google Scholar 

  5. Smith R, Levy P. Ferrario, C, for the Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group: Value of Noninvasive Hemodynamics to Achieve Blood Pressure Control in Hypertensive Subjects. Hypertension. 2006;47:771–7.

    Article  CAS  PubMed  Google Scholar 

  6. Krzesiński P, Gielerak G, Kowal J. A “patient-tailored” treatment of hypertension with use of impedance cardiography: A randomized, prospective and controlled trial. Med Sci Monit. 2013;19:242–50. The most recent randomized trial using hemodynamic measurements to guide hypertension treatment in patients with mild to moderate hypertension.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Tarazi RC. The hemodynamics of hypertension. In: Genest J, Kuchel O, Hamet P, Cantin M, editors. Hypertension: physiopathology and treatment. 2nd ed. New York: McGraw-Hill Book Company; 1983. p. pp 15–42.

    Google Scholar 

  8. Lund-Johansen, P: Hemodynamic effects of antihypertensive agents. In: Handbook of Hypertension. edited by DOYLE, A. E., Elsevier Science Publishers B.V., 1988, pp 41-72.

  9. Struyker Boudier H. The interaction of antihypertensive drugs with mechanisms of blood pressure regulation. In: Von Zwieten P, editor. Pharmacology of antihypertensive drugs. Amsterdam: Elsevier; 1984. p. pp 46–65.

    Chapter  Google Scholar 

  10. Laragh JH. Lesson XVI: How to choose the correct drug treatment for each hypertensive patient using a plasma renin-based method and the volume-vasoconstriction analysis. AmJHyper. 2001;14:491–503.

    CAS  Google Scholar 

  11. Laragh J, Sealey J. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure. Am J Hypertens. 2011;24:1164–80.

    Article  CAS  PubMed  Google Scholar 

  12. Egan B, Basile J, Rehman S, Davis P, Grob III C, Riehle J, et al. Plasma Renin Test–Guided Drug Treatment Algorithm for Correcting Patients With Treated but Uncontrolled Hypertension: A Randomized Controlled Trial. Am J Hypertens. 2009;22:792–801.

    Article  CAS  PubMed  Google Scholar 

  13. Brown MJ, Cruickshank JK, Dominczak AF, MacGregor G, Poulter NR, Russell GI, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens. 2003;17:81–6.

    Article  CAS  PubMed  Google Scholar 

  14. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS-Y, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 2002;20:771–7.

    Article  PubMed  Google Scholar 

  15. Grim CE. Evolution of diagnostic criteria for primary aldosteronism: Why is it more common in "drug-resistant" hypertension today? Curr Hypertens Rep. 2004;6:485–92.

    Article  PubMed  Google Scholar 

  16. Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med. 2005;5:55–60.

    Article  PubMed  Google Scholar 

  17. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217–26.

    Article  CAS  PubMed  Google Scholar 

  18. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hyper. 2003;16:925–30.

    Article  CAS  Google Scholar 

  19. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. AmJHyper. 2002;15:333–9.

    CAS  Google Scholar 

  20. Dustan HP, Tarazi RC, Bravo EL. Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Eng J Med. 1972;286:861–6.

    Article  CAS  Google Scholar 

  21. Finnerty Jr FA, Davidov M, Mroczek WJ, Gavrilovich L. Influence of extracellular fluid volume on response to antihypertensive drugs. Circ Res. 1970;XXVI-XXVII:I-71–82.

    Google Scholar 

  22. Dustan HP. Causes of inadequate response to antihypertensive drugs: Volume factors. Hypertension. 1983;5:III-26–30.

    Article  CAS  Google Scholar 

  23. Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. Br MedJ. 1980;281:1101–3.

    Article  CAS  Google Scholar 

  24. Graves JW, Bloomfield RL, Buckalew VM. Plasma volume in resistant hypertension: Guide to pathophysiology and therapy. Am J Med Sci. 1989;298:361–5.

    Article  CAS  PubMed  Google Scholar 

  25. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. JCardiovascPharmacol. 1987;10:S121–31.

    CAS  Google Scholar 

  26. Ventura H, Taler SJ, Strobeck J. Hypertension as a hemodynamic disease: The role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. Am J Hypertens. 2005;18:26S–43.

    Article  PubMed  Google Scholar 

  27. Johns DW, Peach MJ. Factors that contribute to resistant forms of hypertension: Pharmacological considerations. Hypertension. 1988;11:II-88–95.

    Article  CAS  Google Scholar 

  28. Ferrario C, Flack J, Strobeck J, Smits G, Peters C. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. Ther Adv Cardiovasc Dis. 2010;4:5–16.

    Article  PubMed  Google Scholar 

  29. Frieden T, Berwick D. The “Million Hearts” Initiative — Preventing Heart Attacks and Strokes. NEJM. 2011;365(e27):21–4.

    Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Sandra J. Taler declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Sandra J. Taler

Authors
  1. Sandra J. Taler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandra J. Taler.

Additional information

This article is part of the Topical Collection on Antihypertensive Agents: Mechanisms of Drug Action

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Taler, S.J. Individualizing Antihypertensive Combination Therapies: Clinical and Hemodynamic Considerations. Curr Hypertens Rep 16, 451 (2014). https://doi.org/10.1007/s11906-014-0451-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-014-0451-y

Keywords

Search

Navigation